Tower Research Capital (TRC)’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-135
| Closed | -$170 | – | 5260 |
|
|
2025
Q1 | $170 | Buy |
+135
| New | +$239 | ﹤0.01% | 4997 |
|
|
2024
Q4 | – | Sell |
-1,557
| Closed | -$5.37K | – | 5694 |
|
|
2024
Q3 | $5.37K | Sell |
1,557
-4,215
| -73% | -$19.9K | ﹤0.01% | 4286 |
|
|
2024
Q2 | $29.4K | Buy |
5,772
+5,038
| +686% | +$37.8K | ﹤0.01% | 3502 |
|
|
2024
Q1 | $6.22K | Sell |
734
-482
| -40% | -$2.65K | ﹤0.01% | 4407 |
|
|
2023
Q4 | $4.98K | Sell |
1,216
-1,386
| -53% | -$4.15K | ﹤0.01% | 4892 |
|
|
2023
Q3 | $7.81K | Buy |
2,602
+2,144
| +468% | +$48.7K | ﹤0.01% | 4432 |
|
|
2023
Q2 | $14.2K | Sell |
458
-133
| -23% | -$5.51K | ﹤0.01% | 3718 |
|
|
2023
Q1 | $29K | Buy |
591
+521
| +744% | +$15.1K | ﹤0.01% | 3018 |
|
|
2022
Q4 | $2K | Buy |
+70
| New | +$2.62K | ﹤0.01% | 5329 |
|
|
2022
Q3 | – | Sell |
-370
| Closed | -$15K | – | 6057 |
|
|
2022
Q2 | $15K | Buy |
+370
| New | +$16.7K | ﹤0.01% | 4055 |
|
|
2022
Q1 | – | Sell |
-229
| Closed | -$14K | – | 6085 |
|
|
2021
Q4 | $14K | Buy |
+229
| New | +$11.3K | ﹤0.01% | 4054 |
|
|
2021
Q2 | – | Sell |
-787
| Closed | -$45K | – | 5465 |
|
|
2021
Q1 | $45K | Buy |
787
+498
| +172% | +$37.6K | ﹤0.01% | 3209 |
|
|
2020
Q4 | $20K | Sell |
289
-1,286
| -82% | -$175K | ﹤0.01% | 3867 |
|
|
2020
Q3 | $400K | Buy |
1,575
+1,487
| +1,690% | +$305K | ﹤0.01% | 1931 |
|
|
2020
Q2 | $15K | Sell |
88
-691
| -89% | -$74.5K | ﹤0.01% | 3808 |
|
|
2020
Q1 | $54K | Buy |
779
+35
| +5% | +$2.73K | ﹤0.01% | 1255 |
|
|
2019
Q4 | $48K | Buy |
744
+701
| +1,630% | +$40.7K | ﹤0.01% | 1359 |
|
|
2019
Q3 | $2K | Buy |
+43
| New | +$2.54K | ﹤0.01% | 3655 |
|
|
2018
Q4 | – | Sell |
-46
| Closed | -$3K | – | 3820 |
|
|
2018
Q3 | $3K | Sell |
46
-46
| -50% | -$2.78K | ﹤0.01% | 3277 |
|
|
2018
Q2 | $5K | Buy |
92
+11
| +14% | +$647 | ﹤0.01% | 3050 |
|
|
2018
Q1 | $4K | Sell |
81
-19
| -19% | -$957 | ﹤0.01% | 2771 |
|
|
2017
Q4 | $6K | Sell |
100
-19
| -16% | -$1.14K | ﹤0.01% | 2796 |
|
|
2017
Q3 | $7K | Buy |
+119
| New | +$7.7K | ﹤0.01% | 3193 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3816 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3636 |
|
|
2016
Q2 | – | Sell |
-67
| Closed | -$3K | – | 4420 |
|
|
2016
Q1 | $3K | Buy |
67
+51
| +319% | +$1.87K | ﹤0.01% | 3048 |
|
|
2015
Q4 | $1K | Sell |
16
-65
| -80% | -$2.68K | ﹤0.01% | 4022 |
|
|
2015
Q3 | $3K | Buy |
81
+49
| +153% | +$2.3K | ﹤0.01% | 3097 |
|
|
2015
Q2 | $2K | Buy |
32
+24
| +300% | +$1.43K | ﹤0.01% | 3691 |
|
|
2015
Q1 | $1K | Buy |
+8
| New | +$506 | ﹤0.01% | 4019 |
|
Other funds holding BCLI
GCM
LWM
WCG
TCM
AIP
Tower Research Capital (TRC)'s BCLI Position: Q2 2025 in Review
Tower Research Capital (TRC) sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2025, closing a stake of 135 shares — an estimated $170 sold.
Tower Research Capital (TRC) first reported a position in BCLI in Q1 2015 and held it in 28 quarters. The position peaked at $400K in Q3 2020. 34 funds tracked by Wall St. Rank hold BCLI as of Q2 2025.
- Tower Research Capital (TRC) reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 135 BRAINSTORM CELL THERAPUTC shares in Q2 2025, an estimated $170.
- Tower Research Capital (TRC) first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 28 quarters.
- Tower Research Capital (TRC)'s BRAINSTORM CELL THERAPUTC position peaked at $400K in Q3 2020.
- 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.